An innovative new public/private collaboration between Cure Alzheimer’s Fund and the National Institute of Mental Health (NIMH) already has started to bear fruit.
SAN DIEGO, July 16, 2013 – Confirming an enzyme in the serine hyrdrolase family as a therapeutic target to slow and potentially reverse the effects of Down syndrome and Alzheimer’s disease is the goal of new research announced today by Abide Therapeutics, in collaboration with researchers at the University of California, San Diego School of Medicine and funded by a grant from the Cure Alzheimer’s Fund.
Cure Alzheimer’s Fund and National Institute of Mental Health Join in Awarding Millions for Whole Genome Sequencing
© 2005-2014 Cure Alzheimer's Fund. All rights reserved.